Stephens Reaffirms “Equal Weight” Rating for Anika Therapeutics (NASDAQ:ANIK)

Stephens reaffirmed their equal weight rating on shares of Anika Therapeutics (NASDAQ:ANIK) in a report issued on Thursday, Benzinga reports. The brokerage currently has a $22.00 price target on the biotechnology company’s stock.

ANIK has been the topic of a number of other research reports. Barrington Research boosted their price objective on Anika Therapeutics from $29.00 to $37.00 and gave the stock an outperform rating in a research report on Thursday. StockNews.com upgraded Anika Therapeutics from a hold rating to a buy rating in a research report on Thursday.

Anika Therapeutics Trading Down 0.7 %

NASDAQ:ANIK traded down $0.17 on Thursday, hitting $25.27. The company had a trading volume of 104,218 shares, compared to its average volume of 85,755. The firm has a 50 day moving average of $24.15 and a two-hundred day moving average of $21.59. The stock has a market capitalization of $369.95 million, a price-to-earnings ratio of -4.47 and a beta of 0.75. Anika Therapeutics has a 52 week low of $16.54 and a 52 week high of $29.25.

Institutional Investors Weigh In On Anika Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP grew its position in shares of Anika Therapeutics by 13.0% in the 4th quarter. GSA Capital Partners LLP now owns 58,376 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 6,738 shares during the last quarter. Meros Investment Management LP bought a new stake in shares of Anika Therapeutics in the 4th quarter valued at about $1,132,000. Barclays PLC grew its position in shares of Anika Therapeutics by 41.3% in the 4th quarter. Barclays PLC now owns 37,826 shares of the biotechnology company’s stock valued at $858,000 after buying an additional 11,061 shares during the last quarter. Nuveen Asset Management LLC grew its position in shares of Anika Therapeutics by 93.6% in the 4th quarter. Nuveen Asset Management LLC now owns 265,476 shares of the biotechnology company’s stock valued at $6,016,000 after buying an additional 128,369 shares during the last quarter. Finally, Occudo Quantitative Strategies LP bought a new stake in shares of Anika Therapeutics in the 4th quarter valued at about $248,000. Institutional investors own 90.79% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally.